March 8, 2006 (Mountain View and San Francisco, CA) – Fenwick & West LLP represented investor Kleiner Perkins Caufield & Byers in its recently announced $12.5 million investment in Novavax, Inc. (Nasdaq: NVAX), which, among other things, develops its Virus Like Particle technology into vaccines for the prevention of infectious diseases such as HIV/AIDS, pandemic flu, seasonal flu and SARS. This is an investment from Kleiner Perkins’ newly created KPCB Pandemic and Bio Defense Fund. Prospect Venture Partners also invested $7.5 million as part of the transaction. Fenwick & West also represented Kleiner Perkins and the Texas Pacific Group in their recent $30 million investment in BioCryst, a Nasdaq company that is developing vaccines for avian flu and seasonal flu. More information about the transaction can be obtained from the Novavax Web site.

The Fenwick & West transaction team consisted of corporate partners Sayre Stevick and Jeffrey Vetter and intellectual property partner Sergio Garcia. Corporate associate Michael Brown also assisted on the transaction.

About Fenwick & West
Fenwick & West provides comprehensive legal services to high technology and life sciences clients of national and international prominence. The firm was recently ranked by MergerMarket as the #1 U.S. Legal Advisor for Technology Industry M&A.